Stock Events

Stock Events

Fate Therapeutics 

$1.23
88
+$0.04+3.36% Monday 20:59

Statistics

Day High
1.26
Day Low
1.14
52W High
1.94
52W Low
0.66
Volume
1,660,829
Avg. Volume
1,576,352
Mkt Cap
141.88M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2MarExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-0.46
-0.4
-0.33
-0.27
Expected EPS
-0.274533
Actual EPS
N/A

Financials

-1,366.46%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
27.26MRevenue
-372.52MNet Income

Analyst Ratings

$6.00Average Price Target
The highest estimate is 7.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FATE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the cell therapy space targeting similar diseases.
Novartis
NVS
Mkt Cap237.61B
Novartis offers CAR-T cell therapies, directly competing in the oncology segment with cell-based therapies.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the CAR-T therapy space, similar to Fate's focus.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics focuses on allogeneic CAR-T therapies, directly competing with Fate's off-the-shelf cell therapy approach.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics is involved in genome editing and gene therapy, competing in the broader cell and gene therapy market.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops gene therapies for genetic diseases, indirectly competing in the cell and gene therapy sector.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has investments in gene therapy and CAR-T cell therapy, making it a competitor in the cell therapy market.
First Trust Indxx NextG
NXTG
Mkt Cap0
NextCure focuses on novel immunomedicines, competing in the immune-oncology market with a focus on novel cell therapies.

About

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Show more...
CEO
Dr. Bahram Valamehr M.B.A., Ph.D.
Employees
181
Country
US
ISIN
US31189P1021

Listings

XNAS
US
FATE
F
DE
F6T.F
BOATS
BOATS
FATE.BOATS

0 Comments

Share your thoughts

FAQ

What is Fate Therapeutics stock price today?▼
The current price of FATE is $1.23 USD — it has increased by +3.36% in the past 24 hours. Watch Fate Therapeutics stock price performance more closely on the chart.
What is Fate Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Fate Therapeutics stocks are traded under the ticker FATE.
Is Fate Therapeutics stock price growing?▼
FATE stock has fallen by -6.11% compared to the previous week, the month change is a +24.7% rise, over the last year Fate Therapeutics has showed a -3.15% decrease.
What is Fate Therapeutics market cap?▼
Today Fate Therapeutics has the market capitalization of 141.88M
When is the next Fate Therapeutics earnings date?▼
Fate Therapeutics is going to release the next earnings report on March 02, 2026.
What were Fate Therapeutics earnings last quarter?▼
FATE earnings for the last quarter are -0.27 USD per share, whereas the estimation was -0.29 USD resulting in a +7.58% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Fate Therapeutics revenue for the last year?▼
Fate Therapeutics revenue for the last year amounts to 27.26M USD.
What is Fate Therapeutics net income for the last year?▼
FATE net income for the last year is -372.52M USD.
How many employees does Fate Therapeutics have?▼
As of February 03, 2026, the company has 181 employees.
In which sector is Fate Therapeutics located?▼
Fate Therapeutics operates in the Health Care sector.
When did Fate Therapeutics complete a stock split?▼
Fate Therapeutics has not had any recent stock splits.
Where is Fate Therapeutics headquartered?▼
Fate Therapeutics is headquartered in San Diego, US.